These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [Fulminant type 1 diabetes mellitus]. Author: Imagawa A, Hanafusa T. Journal: Rinsho Byori; 2010 Mar; 58(3):216-24. PubMed ID: 20408439. Abstract: Fulminant type 1 diabetes is a novel subtype characterized by a markedly rapid progression and almost complete destruction of pancreatic beta cells. The number of patients in Japan has been speculated to be 5,000-7,000. A marked decrease of beta cells in addition to alpha cells and mononuclear cell infiltration both in the endocrine and exocrine pancreas are characteristic pathological findings in recent-onset fulminant type 1 diabetes. Laboratory examinations have revealed a high blood glucose level, near normal hemoglobin A1c, ketosis or ketoacidosis, elevation of serum pancreatic exocrine enzymes, and absence of anti-islet autoantibodies such as anti-glutamic acid decarboxylase (GAD) antibody or anti-insulinoma-associated antigen-2 (IA-2) antibody at disease onset. Genetic factors of HLA-DR-DQ, CTLA-4, and HLA-B are associated with this subtype. Both diagnostic criteria for screening and establishing have been announced by the Japan Diabetes Society. In approximately half of fulminant type 1 diabetes, HbA1c was lower than 6.2% at disease onset, indicating that newly proposed diagnostic criteria of diabetes (HbA1c > or = 6.5%) from the joint committee of the American Diabetes Society, the European Association for the Study of Diabetes, and the International Diabetes Federation are not applicable to fulminant type 1 diabetes. In conclusion, all medical practitioners must remember that fulminant type 1 diabetes, an extremely rapidly progressing type of diabetes, does exist, and must pay special attention to avoid overlooking this disease.[Abstract] [Full Text] [Related] [New Search]